Amgen has launched a direct-to-consumer (DTC) platform offering a 60% discount on its cholesterol-lowering drug, Repatha, positioning the United States with the lowest price among G7 nations. This initiative reflects a significant shift in the pharmaceutical industry, as major drug manufacturers increasingly adopt DTC strategies to address rising pressures for drug affordability.
The move comes in the context of ongoing discussions around U.S. drug pricing reform, particularly following calls from former President Donald Trump for more accessible pricing models. By providing a substantial discount directly to consumers, Amgen not only enhances patient access to essential medications but also sets a precedent for competitive pricing in the market.
The implications of this DTC approach could reshape the landscape for pharmaceutical pricing, encouraging other companies to follow suit. As the industry navigates regulatory scrutiny and public demand for transparency, Amgen’s strategy may serve as a benchmark for balancing profitability with patient accessibility.
Get started today with Solo access →
